Closure of Biomedical Innovation Fund I

Wellington Management, one of the world’s largest independent investment management firms, today announced the final close of the oversubscribed Wellington Biomedical Innovation Fund I. The Fund will invest in private biotechnology companies that are focused on drug discovery and development, and are seeking capital to advance their scientific programs.

PRESS RELEASE

Wellington Management Announces Close of Biomedical Innovation Fund I at $393M

BOSTON, HONG KONG, LONDON, November 18, 2019 – Wellington Management (“Wellington” or the “Firm”), one of the world’s largest independent investment management firms, today announced the final close of the oversubscribed Wellington Biomedical Innovation Fund I (“Fund”).

The Fund will invest in private biotechnology companies focused on drug discovery and development, and seeking capital to advance their scientific programs.

Bob Deresiewicz, MD, Senior Managing Director at Wellington, said, “Biotechnology represents an exciting investment area, driven by an explosion in fundamental biomedical knowledge and a growing ability of companies to deploy that knowledge in the service of breakthrough drug discovery. We pursue an evidence-based approach to investing, seeking to leverage our biomedical, scientific, and industry expertise to identify promising assets that could meaningfully advance medical practice.”

Chris Kirk, the President of Wellington Alternative Investments, added, “This new sector-focused fund is the next step in expanding our private investment capabilities as we look for new opportunities to create long-term value for our investors. We believe our portfolio companies will benefit from partnering with Wellington and our extensive team of tenured industry analysts, who bring sector-level insights and public market expertise in support of their strategic growth plans.”

The close of Wellington’s Biomedical Innovation Fund I expands the Firm’s private investment platform, which now includes both health care and late stage growth funds totaling $2.7 billion. The funds’ global investor base includes public and private pension plans, insurance companies, corporations, and family offices.

About Wellington Management

Tracing its history to 1928, Wellington Management is one of the world’s largest independent investment management firms, serving as a trusted adviser to over 2,200 institutional and private clients located in more than 60 countries and managing over USD 1 trillion of assets.*

Wellington offers comprehensive investment management capabilities that span nearly all segments of the global capital markets. The firm’s only business is investment management and its mission is to exceed the investment objectives and service expectations of its clients worldwide. Wellington’s solutions draw on a robust body of proprietary research and a collaborative culture that encourages independent thought and healthy debate.

For more information, visit wellington.com.

*For Wellington Management group of companies as at 30 September 2019.

Media
Prosek Partners (on behalf of Wellington Management)
Abby McAleney
[email protected]
(646) 503-6025

RECOMMENDED FOR YOU

Redefining “value” for a modern economy
Value stocks are cheap and growth stocks are expensive. End of story, right? Our Fundamental Factor Team argues that the traditional tools for measuring value are out of date and offers a more nuanced view.
September 2020
Redefining "value" for a modern economy
,
Climate change and emerging markets: Assessing opportunities and challenges
Emerging markets are on the front lines of climate change. Aware of the challenges, many EM companies are developing solutions, shifting business models, and realigning corporate policies to help them prepare. Two of our EM portfolio managers share insights on the investing landscape and offer a framework for incorporating climate-related themes into a portfolio.
September 2020
Climate change and emerging markets: Assessing opportunities and challenges
,
Studying outsiders: Blending the advantages of public and private equity
Learn why we believe a longer-term public market approach focused on strong capital allocation could combine the benefits of public and private equity.
August 2020
Studying outsiders: Blending the advantages of public and private equity
,
Investment bytes – Asia tech <span>Part six: the world’s hub of innovation</span>
We profile Asia technology in the 2020s, outlining the long-term case for the sector after its strong rebound in recent months.
July 2020
Investment bytes – Asia tech Part six: the world’s hub of innovation
,
Where can insurers find compelling returns?
In our mid-year insurance webcast recap, we shed light on the early signs of recovery that we are observing and where they intersect favorably for insurers from an investment standpoint.
July 2020
Where can insurers find compelling returns?
,
Asking private companies to show their ESG<br> credentials
ESG issues are a growing area of focus in the public market, but what about the private market? Our co-head of Private Investments and our director of ESG, Private Investments, argue for informed and active ownership from the initial investment until the IPO.
July 2020
Asking private companies to show their ESG
credentials
,
A is for allocation: The rationale for increasing<br> exposure to China
Allocations to China equity are widely recommended, but how much is appropriate and why? We consider several reasons why this may make sense for offshore investors.
June 2020
A is for allocation: The rationale for increasing
exposure to China
,
Reinventing the core: The role of fundamental extension (140/40) strategies
Are we again headed toward single-digit equity returns as the new norm? Extension strategies may help improve the outlook by generating viable alpha and enabling investors to achieve "more from core."
June 2020
Reinventing the core: The role of fundamental extension (140/40) strategies
,